December 14, 2023

Maze Therapeutics

Maze Therapeutics Announces Initiation of Dosing in Phase 1 Trial Evaluating MZE829, a Novel Oral APOL1 Inhibitor, as a Potential Treatment for APOL1 Kidney Disease

December 13, 2023

CARGO Therapeutics

CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results

December 11, 2023

Maze Therapeutics

Maze Therapeutics Announces FTC Action Seeking to Block Collaboration and License Agreement with Sanofi Regarding MZE001, a Potential Oral Substrate Reduction Therapy for Pompe Disease

December 07, 2023

ARTBIO

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies

December 06, 2023

CARGO Therapeutics

CARGO Therapeutics Announces Scientific Advisory Board

Load More

Sign up for weekly portfolio news.